The Beauty Health Company (NASDAQ:SKIN) Receives Consensus Rating of “Reduce” from Brokerages

Shares of The Beauty Health Company (NASDAQ:SKIN) have been given an average recommendation of “Reduce” by the eight analysts that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $2.42.

SKIN has been the topic of several recent analyst reports. TD Cowen cut their target price on shares of Beauty Health from $1.65 to $1.50 and set a “hold” rating on the stock in a report on Monday. Zacks Research cut shares of Beauty Health from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 21st. Benchmark reissued a “hold” rating on shares of Beauty Health in a report on Friday. Canaccord Genuity Group restated a “hold” rating and issued a $1.50 price objective on shares of Beauty Health in a research report on Friday. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $1.60 target price on shares of Beauty Health in a report on Wednesday, January 14th.

Beauty Health Trading Down 5.9%

Shares of SKIN stock opened at $1.20 on Tuesday. The stock has a market capitalization of $152.36 million, a PE ratio of -5.97 and a beta of 1.20. Beauty Health has a 1-year low of $0.78 and a 1-year high of $2.69. The business has a 50-day moving average of $1.27 and a 200 day moving average of $1.50. The company has a debt-to-equity ratio of 3.94, a current ratio of 1.66 and a quick ratio of 1.40.

Beauty Health (NASDAQ:SKIN) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Beauty Health had a negative return on equity of 15.40% and a negative net margin of 3.16%.The business had revenue of $82.37 million for the quarter, compared to analysts’ expectations of $78.07 million. As a group, sell-side analysts anticipate that Beauty Health will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On Beauty Health

Several institutional investors and hedge funds have recently bought and sold shares of SKIN. Invesco Ltd. grew its position in shares of Beauty Health by 6.6% in the 2nd quarter. Invesco Ltd. now owns 98,427 shares of the company’s stock worth $188,000 after buying an additional 6,059 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Beauty Health by 45.5% during the second quarter. ProShare Advisors LLC now owns 23,447 shares of the company’s stock valued at $45,000 after acquiring an additional 7,336 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Beauty Health by 5.7% during the third quarter. Rhumbline Advisers now owns 150,124 shares of the company’s stock valued at $299,000 after acquiring an additional 8,142 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Beauty Health by 33.5% in the second quarter. The Manufacturers Life Insurance Company now owns 41,488 shares of the company’s stock worth $79,000 after acquiring an additional 10,410 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in Beauty Health in the third quarter valued at $26,000. Hedge funds and other institutional investors own 93.26% of the company’s stock.

About Beauty Health

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.